We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INDV icon
226
Indivior Pharmaceuticals
INDV
$4.58B
– –
-54,057
Closed -$672K
IRON icon
227
Disc Medicine
IRON
$2.97B
– –
-4,196
Closed -$266K
JNJ icon
228
CALL
Johnson & Johnson
JNJ
$625B
– –
-10,000
Closed -$1.45M
KOD icon
229
Kodiak Sciences
KOD
$2.84B
– –
-23,700
Closed -$236K
KPTI icon
230
Karyopharm Therapeutics
KPTI
$48M
– –
-1,333
Closed -$13.5K
LUNG icon
231
Pulmonx
LUNG
$87.6M
– –
-28,221
Closed -$192K
DFTX
232
Definium Therapeutics
DFTX
$6.12B
– –
-25,000
Closed -$174K
MRK icon
233
Merck
MRK
$318B
– –
-2,440
Closed -$243K
MRNA icon
234
Moderna
MRNA
$23.6B
– –
-9,000
Closed -$374K
PLRX icon
235
Pliant Therapeutics
PLRX
$65M
– –
-134,798
Closed -$1.78M
PTGX icon
236
CALL
Protagonist Therapeutics
PTGX
$9.44B
– –
-132,000
Closed -$5.1M
PYXS icon
237
Pyxis Oncology
PYXS
$236M
– –
-10,000
Closed -$15.6K
QURE icon
238
uniQure
QURE
$3.22B
– –
-10,000
Closed -$177K
RARE icon
239
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-8,000
Closed -$337K
RGNX icon
240
CALL
Regenxbio
RGNX
$708M
– –
-17,800
Closed -$138K
RPRX icon
241
Royalty Pharma
RPRX
$25.3B
– –
-49,963
Closed -$1.27M
SDGR icon
242
Schrodinger
SDGR
$1.36B
– –
-25,147
Closed -$485K
SLRN
243
DELISTED
ACELYRIN
SLRN
– –
-444,967
Closed -$1.4M
SNY icon
244
Sanofi
SNY
$104B
– –
-99,600
Closed -$4.8M
TARS icon
245
CALL
Tarsus Pharmaceuticals
TARS
$2.84B
– –
-5,000
Closed -$277K
VERU icon
246
Veru
VERU
$37.4M
– –
-5,072
Closed -$33K
VIGL
247
DELISTED
Vigil Neuroscience
VIGL
– –
-15,543
Closed -$26.4K
XBI icon
248
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.3B
– –
-50,000
Closed -$4.5M
BKHA
249
Black Hawk Acquisition Corp
BKHA
$48.9M
– –
-15,000
Closed -$156K
ASPCU
250
A SPAC III Acquisition Corp Unit
ASPCU
$62.5M
– –
-215,000
Closed -$2.17M
7 8 9
10
11

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.